However, strategies to inhibit LAG-3 may be even more promising as antibodies that target LAG-3 were shown to enhance cytotoxic T cell activation and may inhibit Treg-induced immunosuppressive activity as elevated levels of a LAG-3+ subpopulation of Tregs was found at tumor sites and in peripheral blood mononuclear cells of patients with melanoma or colorectal cancer (100). Here, LAG3 is linked to melanoma.